Cyclosporine For The Treatment Of Covid-19(+)

Cyclosporine For The Treatment Of Covid-19(+)

Publication date: Jul 30, 2020

Phase IIa clinical trial in which 75 non-ICU hospital inpatients will be randomized 2:1 to 7 days of Neoral (2.5mg/kg PO BID) + standard of care (SOC) or no CSA + SOC. The primary endpoint is disease severity based on the World Health Organization (WHO) COVID Ordinal Outcomes Scale, on day 14. Secondary endpoints include safety and changes in serum inflammatory markers.

Concepts Keywords
Air Severity illness
Ambient SARS
ANC Allergy
Angiotensin Converting Enzyme Renal disease diabetes
ARDS Viral infections
Avian CSA therapy Psoriasis
Biomarkers Coronaviruses HIV hepatitis
Blockade Hyperinflammatory syndrome
Bronchitis Avian infection bronchitis
Calcineurin Mild flu
Calcineurin Inhibitor Immunosuppression decrease seizure
Capsules Renal transplantation
Cardinal Immunosuppression
Cardiovascular Disease Liver heart transplants
Chemokines Mechanical ventilation
Chronic Diseases Respiratory diseases
Clinical Trial Animal diseases
Comorbidities Medical specialties
Coronavirus Zoonoses
Cough Sarbecovirus
Cross Bat virome
Cyclophilin Coronavirus disease
Cyclosporine Human coronavirus NL63
Cytokine Human coronavirus 229E
Cytokine Storm Transplantation
Cytokines Correlative Correlative protocol
Cytopenias
Deep Vein Thrombosis
Dexamethasone
Diabetes Mellitus
Dimer
Endothelial
Epithelial
FDA
Feline
Ferritin
Fever
FGF2
Gastroenteritis
GMCSF
Hepatitis
HIV
Hospital
Hyperactivity
Immunosuppressive
Immunosuppressive Drugs
Incidence
Incubation Period
IND
Infection
Inhibitor
Intensive Care Unit
Italy
Kidney
Liver
Liver Disease
Lymphocyte
Lymphocytes
Macrophage
Macrophages
Madrid
Malaise
MAS
Mechanical Ventilation
MERS
Mortality
NFAT
Novartis
Nucleocapsid
Organ
Oxygen
Pandemic
PCR
PDGF
Phase IIa
Phosphatase
Phosphorylation
Placebo
Plaque Psoriasis
Plasma
Porcine
Primary Endpoint
Prophylaxis
Protocol
Psoriasis
Pulmonary
Pyroptosis
Receptor
Receptors
Reference Letter
Renal Disease
Renal Transplantation
Respiratory Failure
Respiratory Tract
Rheumatoid Arthritis
SARS
Sepsis
Serotypes
Serum
Spain
Syndrome
T Cell
TNF
Transmembrane
United Kingdom
VEGF
Viral
Viral Load
Viral Replication
Virus
Viruses
WBC
WHO

Semantics

Type Source Name
drug DRUGBANK Ciclosporin
disease MESH infection
disease MESH emergency
drug DRUGBANK Oxygen
drug DRUGBANK Medical air
drug DRUGBANK Dexamethasone
disease MESH Allergy
disease MESH hypertension
drug DRUGBANK Hydroxychloroquine
disease MESH psychiatric illness
drug DRUGBANK Cholesterol
drug DRUGBANK Tacrolimus
disease MESH contraindication
disease IDO immunosuppression
disease MESH malignancy
disease IDO susceptibility
disease MESH development

Original Article